Filter By Category
Archives
Share on -
AVUTOMETINIB
Generic Name: AVUTOMETINIB
ABSTRACT -
Avutometinib is an oral small-molecule RAF/MEK pathway inhibitor used in combination with defactinib where approved for selected KRAS-mutated recurrent low-grade serous ovarian cancer. Its molecular formula is C₂₁H₁₈FN₅O₅S, with molecular weight approximately 471.47 g/mol. The chemical representation above shows the 2D skeletal structure.
This document is for structured API information only. It is not a prescribing guide. Clinical use, if any, must follow the approved local label, trial protocol, and specialist medical supervision.
DOSAGE-
- Dosage should be determined only by a qualified oncology professional.
- Use only according to the approved local product label for the specific indication and combination regimen.
- Dose modifications may be required for ocular toxicity, rash, hepatotoxicity, increased creatine phosphokinase, or other adverse reactions.
- Do not change, stop, or restart treatment without medical supervision.
SIDE EFFECTS-
Possible side effects and safety concerns include:
- Rash, acneiform dermatitis, dry skin, itching, or severe cutaneous adverse reactions
- Visual impairment, dry eye, floaters, retinal pigment epithelial detachment, or other ocular toxicity
- Nausea, diarrhea, vomiting, abdominal pain, dyspepsia, or stomatitis
- Fatigue, edema, musculoskeletal pain, increased creatine phosphokinase, or muscle symptoms
- Liver enzyme abnormalities, cytopenias, infection symptoms, or laboratory changes may occur
ALLERGIC REACTIONS -
Hypersensitivity to Avutometinib or related compounds/products may occur. Symptoms may include:
- Immediate urticaria, itching, flushing, or generalized rash
- Facial, lip, tongue, or throat swelling
- Wheezing, chest tightness, or breathing difficulty
- Dizziness, fainting, severe hypotension, or collapse
- Anaphylaxis, although uncommon, requires emergency medical treatment
Important: Patients who develop an allergic reaction to Avutometinib should seek immediate medical attention and inform all future healthcare providers of the allergy.
DRUG INTERACTIONS-
Avutometinib may interact with certain medicines, biologics, vaccines, protocols, or clinical conditions. Caution is needed with:
- Strong or moderate CYP3A4 inhibitors or inducers may affect the combination regimen and generally require avoidance or careful management.
- Warfarin and other anticoagulant therapy require careful coordination due to bleeding/INR concerns.
- Gastric acid-reducing agents may alter defactinib exposure in the approved co-pack regimen.
- Patients should report all medicines, supplements, and herbal products.
Patients should inform healthcare providers about all prescription medicines, over-the-counter medicines, herbal products, vaccines, and supplements they are using.
PREAUTIONS–
- Perform ophthalmic assessment and monitor promptly for visual symptoms.
- Monitor liver tests, creatine phosphokinase, blood counts, skin reactions, and gastrointestinal toxicity.
- Use sun protection and supportive dermatologic care when clinically appropriate.
- Pregnancy and lactation require individualized oncology review.
WARNINGS –
- Serious ocular toxicity, skin toxicity, hepatotoxicity, and muscle injury can occur.
- Fetal harm is possible based on mechanism of action; follow label guidance for contraception.
- Use only for approved settings or protocol-defined use under oncology supervision.
- Keep out of reach of children.
Share on -
. Developed by